0000950103-15-009405.txt : 20151208 0000950103-15-009405.hdr.sgml : 20151208 20151208124822 ACCESSION NUMBER: 0000950103-15-009405 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20151208 FILED AS OF DATE: 20151208 DATE AS OF CHANGE: 20151208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biotie Therapies Corp. CENTRAL INDEX KEY: 0001579695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: H9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37423 FILM NUMBER: 151274634 BUSINESS ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 BUSINESS PHONE: 358-2-274-8900 MAIL ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 6-K 1 dp61763_6k.htm FORM 6-K

  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December, 2015

 

 

Commission File Number: 001-37423

 

Biotie Therapies Oyj

(Exact name of registrant as specified in its charter)

 

Biotie Therapies Corp.

(Translation of registrant’s name into English)

 

Joukahaisenkatu 6, FI-20520

Turku, Finland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒   Form 40-F  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes     No ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   No ☒
         
         
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BIOTIE THERAPIES CORP.  
       
       
      By: /s/ David Cook  
        Name: David Cook  
        Title: Chief Financial Officer  

 

Date: December 8, 2015

 

 

 

EXHIBIT INDEX

 

Exhibit Number Description  
99.1 Stock Exchange Release dated December 8, 2015 (9:00 a.m. EET): Biotie’s financial information in 2016

 

 

 EX-99.1 2 dp61763_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

BIOTIE THERAPIES CORP. STOCK  EXCHANGE  RELEASE December 8, 2015 at 9:00 a.m.

 

Biotie’s financial information in 2016

 

Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announce the dates it will disclose financial information in 2016.

 

The Company’s financial statement release for year 2015 will be published on March 18, 2016. Biotie acknowledges that this is later than the date for similar releases during previous years. The listing of Biotie’s American Depositary Shares (ADSs) on the NASDAQ Global Select Market has increased the Company’s corporate governance and related requirements and, consequently, additional time is required for the preparation of the financial statement release.

 

The financial statements for year 2015 and corporate governance statement 2015 (separately from the Board of Directors’ report) will be published during the week commencing March 21, 2016 (week 12/2016).

 

The interim financial reports from the remainder of the year will be published as follows:

 

Interim report January - March 2016 May 12, 2016
Interim report for January - June 2016   August 11, 2016
Interim report for January - September 2016 November 10, 2016

 

Biotie's Annual General Meeting is planned to be held on April 20, 2016. Biotie's Board of Directors will summon the Meeting at a later date. A shareholder is entitled to have considered by the General Meeting a matter falling within the remit of the General Meeting provided that the matter is presented in writing in time for it to be included in the notice convening the Meeting. A request is considered as having been received in good time if the Board of Directors has been notified of such a request no later than March 1, 2016. Such a request should be sent to: Biotie Therapies Corp. Board of Directors, Joukahaisenkatu 6, FI-20520 Turku, Finland.

 

Turku, December 8, 2015

 

Biotie Therapies Corp.

 

Timo Veromaa
President and CEO

 

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

 

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media